Based on the drop of prostate-specific membrane antigen (PSA) levels, and complete therapeutic response on [68Ga]Ga-PSMA-11 PET/CT scans, Kratochwil et al. reported the efficacy of 225Ac-labeled PSMA small molecule inhibitor PSMA-617 ([225Ac]Ac-PSMA-617) in patients with an aggressive type of PCa [193]. Here, FOLH1 is linked to posterior cortical atrophy.